CY1110188T1 - Αντισωματα κατα συζυγων φωσφορυλχολινης - Google Patents

Αντισωματα κατα συζυγων φωσφορυλχολινης

Info

Publication number
CY1110188T1
CY1110188T1 CY20101100630T CY101100630T CY1110188T1 CY 1110188 T1 CY1110188 T1 CY 1110188T1 CY 20101100630 T CY20101100630 T CY 20101100630T CY 101100630 T CY101100630 T CY 101100630T CY 1110188 T1 CY1110188 T1 CY 1110188T1
Authority
CY
Cyprus
Prior art keywords
spoines
phosphylcholine
antibodies against
immunization
treatment
Prior art date
Application number
CY20101100630T
Other languages
English (en)
Inventor
Faire Ulf De
Johan Frostegård
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of CY1110188T1 publication Critical patent/CY1110188T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Προσδιορίσθηκαν τα επίπεδα αυτοαντισωμάτων IgG και IgM κατά της φωσφορυλχολίνης σε άτομα με υπέρταση (διαστολική πίεση › 95 mmHg) κατά τον αρχικό χρόνο ώστε να προσδιορισθεί η σημασία των αντισωμάτων για την ανάπτυξη αθηροσκληρώσεως. Τα αποτελέσματα υποδεικνύουν ότι η αύξηση του πάχους του έσω-ενδιάμεσου χιτώνα (ΙΜΤ) κατά την επανεξέταση τέσσερα έτη μετά τον αρχικό χρόνο ήταν σημαντικά λιγότερο εμφανής σε άτομα με υψηλό τίτλο αυτοαντισωμάτων, ιδιαίτερα αυτοαντισωμάτων IgM, κατά της φωσφορυλχολίνης. Συνεπώς η παρουσία ή η απουσία αυτοαντισωμάτων, ιδιαίτερα αυτοαντισωμάτων IgM, κατά της φωσφορυλχολίνης σχετίζεται με έναν αυξημένο ή μειωμένο κίνδυνο αναπτύξεως καρδιαγγειακών νόσων. Στην παρούσα εφεύρεση προτείνεται μία μέθοδος προσδιορισμού αντισωμάτων, ιδιαίτερα αντισωμάτων IgM, κατά της φωσφορυλχολίνης, για τον εντοπισμό ατόμων τα οποία κινδυνεύουν να αναπτύξουν ισχαιμικές καρδιαγγειακές νόσους. Πειράματα σε ζώα υποδεικνύουν ότι μπορούν να ανιχνευθούν μέτρια έως υψηλά επίπεδα αντισωμάτων, ιδιαίτερα αντισωμάτων IgM, στο πλάσμα μετά από ενεργό ανοσοποίηση με ένα συζυγές αιμοκυανίνης λεπάδας (ΚΙ_Η)-φωσφορυλχολίνης. Προτείνεται μία φαρμακευτική σύνθεση περιλαμβάνουσα ένα συζυγές φωσφορυλχολίνης (ενεργή ανοσοποίηση) ή ένα παρασκεύασμα αντισωμάτων, για παράδειγμα ένα μονοκλωνικό αντίσωμα, με επιλεκτικότητα προς ένα συζυγές φωσφορυχολίνης (παθητική ανοσοποίηση) και η χρήση αυτών των συνθέσεων ως ενεργών ή παθητικών ανοσογόνων στην αγωγή ή την πρόληψη της αθηροσκληρώσεως.
CY20101100630T 2004-04-15 2010-07-07 Αντισωματα κατα συζυγων φωσφορυλχολινης CY1110188T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138404P 2004-04-15 2004-04-15
EP06077208A EP1797893B1 (en) 2004-04-15 2005-04-15 Antibodies against phosphorylcholine conjugates

Publications (1)

Publication Number Publication Date
CY1110188T1 true CY1110188T1 (el) 2015-01-14

Family

ID=34981497

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100630T CY1110188T1 (el) 2004-04-15 2010-07-07 Αντισωματα κατα συζυγων φωσφορυλχολινης
CY20101101123T CY1111659T1 (el) 2004-04-15 2010-12-06 Μεθοδος αξιολογησεως του κινδυνου ισχαιμικης καρδιαγγειακης νοσου με τη χρηση συζυγων φωσφορυλχολινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20101101123T CY1111659T1 (el) 2004-04-15 2010-12-06 Μεθοδος αξιολογησεως του κινδυνου ισχαιμικης καρδιαγγειακης νοσου με τη χρηση συζυγων φωσφορυλχολινης

Country Status (15)

Country Link
US (4) US8012483B2 (el)
EP (3) EP1797893B1 (el)
JP (2) JP4891228B2 (el)
CN (4) CN105699669A (el)
AT (2) ATE463254T1 (el)
AU (2) AU2005233361B2 (el)
CA (2) CA2562550C (el)
CY (2) CY1110188T1 (el)
DE (2) DE602005020474D1 (el)
DK (2) DK1735349T3 (el)
ES (2) ES2362222T3 (el)
PL (2) PL1797893T3 (el)
PT (2) PT1735349E (el)
SI (2) SI1735349T1 (el)
WO (1) WO2005100405A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525462A (ja) 2004-12-22 2008-07-17 エイボン プロダクツ インコーポレーテッド しわの外観を減少させるための方法および組成物
WO2006086288A2 (en) * 2005-02-07 2006-08-17 The Regents Of The University Of California Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells
AU2007277146B2 (en) * 2006-07-26 2011-10-20 Inova Diagnostics, Inc. Compositions and methods for diagnosing patients with acute atherosclerotic syndromes
EP2115466A4 (en) * 2006-12-22 2010-07-28 Abbott Lab HEART CIRCUIT AUTOIMMUNE DISEASE TEST GROUP AND METHOD FOR USE THEREOF
MX2010004885A (es) * 2007-10-30 2010-08-04 Athera Biotechnologies Ab Diagnostico y metodos terapeuticos y composiciones para enfermedades cardiovasculares.
WO2010003602A1 (en) 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for alzheimer's disease
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US20130004491A1 (en) * 2010-03-04 2013-01-03 Frostegaard Johan Antibodies Against Phosphorylcholine In Combination Therapy with Biologic Agents
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
JP5904553B2 (ja) * 2010-11-17 2016-04-13 国立大学法人愛媛大学 自己免疫疾患に関与するタンパク質の解析方法及び該疾患の検査方法
EP2742068B1 (en) * 2011-08-09 2019-04-03 Athera Biotechnologies AB New antibodies against phosphorylcholine
US9796786B2 (en) 2011-08-09 2017-10-24 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
CN105102485B (zh) 2013-02-05 2019-04-19 特普塞拉公司 磷酸胆碱缀合物及其用途
US10046021B2 (en) 2013-02-05 2018-08-14 Tpcera Ltd. Phosphorylcholine conjugates and uses thereof
US11065319B2 (en) * 2014-02-04 2021-07-20 3Dt Holdings, Llc Methods for diagnosing and reducing incidences of cardiac allograft rejection
US10500260B2 (en) * 2014-02-04 2019-12-10 3Dt Holdings, Llc Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
WO2016060096A1 (ja) 2014-10-15 2016-04-21 日油株式会社 ホスホリルコリン基含有化合物およびホスホリルコリン複合体
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
WO2018220224A1 (en) * 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2024028192A1 (de) 2022-08-04 2024-02-08 Pentracor Gmbh Verwendung von phosphocholin-humanserumalbumin-konjugaten zur blockade von c-reaktivem protein

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
JPS6251699A (ja) * 1985-08-30 1987-03-06 Nichirei:Kk 単クロ−ン性抗体およびそれを用いる測定法
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ES2070820T3 (es) 1986-08-06 1995-06-16 Scripps Clinic Res Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
WO1990012632A1 (en) * 1989-04-19 1990-11-01 The United States Of America, Represented By The Secretary, United States Department Of Commerce Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
CA2098101A1 (en) 1990-12-10 1992-06-10 Carl R. Alving A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
JPH07504817A (ja) * 1992-03-03 1995-06-01 ザ ロックフェラー ユニヴァーシティ Ｂ２９（Ｉｇ‐βまたはＩｇ−γ）を含むレセプタ複合体およびその利用
WO1994014454A1 (en) * 1992-12-29 1994-07-07 Entremed, Inc. Vaccines against sterols
AU6268894A (en) 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) * 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
DK1095271T3 (da) 1998-07-03 2003-12-15 Athera Biotechnologies Ab Fremgangsmåde til diagnose af hjertekar-sygdomme og tidlig aterosklerose
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
CA2389849A1 (en) * 1999-10-26 2001-05-10 Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
WO2001088547A2 (en) 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2004091520A2 (en) * 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis

Also Published As

Publication number Publication date
EP1797893A2 (en) 2007-06-20
AU2005233361B2 (en) 2011-02-24
JP5366987B2 (ja) 2013-12-11
JP2011099871A (ja) 2011-05-19
US20160131661A1 (en) 2016-05-12
AU2011202334B2 (en) 2012-12-06
US20140186360A1 (en) 2014-07-03
PL1735349T3 (pl) 2011-03-31
SI1797893T1 (sl) 2010-08-31
CN1968965B (zh) 2015-12-16
CN103908669A (zh) 2014-07-09
PT1735349E (pt) 2010-12-14
ES2357606T3 (es) 2011-04-28
WO2005100405A2 (en) 2005-10-27
DK1797893T3 (da) 2010-08-02
JP4891228B2 (ja) 2012-03-07
US10222382B2 (en) 2019-03-05
WO2005100405A3 (en) 2006-04-13
US20120039895A1 (en) 2012-02-16
CN103743898B (zh) 2019-02-05
DE602005020474D1 (de) 2010-05-20
CA2562550C (en) 2013-09-24
SI1735349T1 (sl) 2010-12-31
PT1797893E (pt) 2010-07-14
ATE463254T1 (de) 2010-04-15
EP2258728A1 (en) 2010-12-08
CA2776927C (en) 2014-08-12
US8012483B2 (en) 2011-09-06
DK1735349T3 (da) 2010-12-06
AU2011202334A1 (en) 2011-06-09
CA2562550A1 (en) 2005-10-27
ATE480778T1 (de) 2010-09-15
EP1735349B1 (en) 2010-09-08
AU2005233361A1 (en) 2005-10-27
JP2008501636A (ja) 2008-01-24
EP1797893B1 (en) 2010-04-07
CN105699669A (zh) 2016-06-22
EP1735349A2 (en) 2006-12-27
CY1111659T1 (el) 2015-10-07
CN103908669B (zh) 2017-07-04
PL1797893T3 (pl) 2010-09-30
CN1968965A (zh) 2007-05-23
CN103743898A (zh) 2014-04-23
US20070286868A1 (en) 2007-12-13
CA2776927A1 (en) 2005-10-27
EP1797893A3 (en) 2007-06-27
ES2362222T3 (es) 2011-06-29
DE602005023428D1 (de) 2010-10-21

Similar Documents

Publication Publication Date Title
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
NL1026089A1 (nl) Scintillator welke een geïntegreerde collimator heeft en werkwijze voor het vervaardigen daarvan.
CY1110606T1 (el) Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
NL1026892A1 (nl) ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie.
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EP2397499A3 (en) Human anti-B7RP1 neutralizing antibodies
BRPI0607304A2 (pt) compostos tendo atividade analgésica e/ou imunoestimulante
DE602006019404D1 (de) Docetaxel-immuntest
ATE476655T1 (de) Doxorubicin-immuntest
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
DE602005026260D1 (de) Natürliche igm-antikörper und inhibitoren davon
FR2864903B1 (fr) Appareil de traitement notamment par laser d'un cancer ou d'un etat precancereux
ITBO20050416A1 (it) Composizione per la cura e/o la prevenzione di attacchi da parte di agenti biologici
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
ECSP067022A (es) Tratamiento de infecciones micóticas
FR2893833B1 (fr) Appareil d'orthopedie dento-faciale.
ITMI20040260A1 (it) Metodo e strumento per la stima geometrica di lesioni di tessuti o organi interni
ATE377608T1 (de) Hemoglobin konjugate
CY1116949T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
ITMO20050086A1 (it) 'dispositivo antifumo per sigarette o simili.'
ES1058260Y (es) Dispositivo para arreglos florales, en especial para coronas funebres.